Government-Owned Inventions; Availability for Licensing, 34693-34694 [E7-12174]
Download as PDF
<![CDATA[
34693
Federal Register / Vol. 72, No. 121 / Monday, June 25, 2007 / Notices
NIH Intramural Research Program (NIH–
IRP). The application for admission into
the Graduate Partnerships Program
(GPP) models many university graduate
school applications, key areas
including: Contact information,
citizenship status, identification of
partnerships to which the student
wishes to apply, educational history,
standardized examination scores, letters
of recommendation, research interests,
personal statement / proposed research,
and NIH investigator for dissertation
research. In addition, race, ethnicity,
gender, and disability questions are
included though optional for
completion; used only for statistical
purposes in evaluating GPP recruiting
efforts and compliance with federal
regulations. The Graduate Student
Training Program application will be
used by the NIH Admission Committees
to identify candidates for admission in
institutional and individual
partnerships.
Frequency of Response: Once.
Affected Public: Individuals. Type of
Respondents: Students pursuing an
advanced degree, Ph.D., who would like
to perform part or all of their
dissertation research in the NIH
Intramural Research Program
laboratories.
The annual reporting burden is
displayed in the following table:
ESTIMATES OF ANNUAL BURDEN HOURS
Estimated
number of respondents
Estimated
number of responses per
respondent
Average burden hours per
response
Estimated total
annual burden
hours requested
Graduate Student Applicants On-Line .............................................................
Post-baccalaureate Applicants On-Line ..........................................................
Collection & Submission of Hardcopy Documents ..........................................
Recommendations (600 × 3) ...........................................................................
Feedback Questions ........................................................................................
100
500
600
1800
200
1
1
1
1
1
0.50
0.50
0.50
0.25
0.25
50
250
300
450
50
Totals ........................................................................................................
3200
........................
........................
1100
Type of respondents
Estimates of capital costs, operating
costs, and/or maintenance costs are
displayed in the following table:
ESTIMATE OF ANNUAL COST TO THE FEDERAL GOVERNMENT
Annualized capital, start-up cost
Amount
Operational/maintenance & purchase components
Amount
Information Collection ...................................................
Application Design, Development, Testing ..................
$0.00
12,000.00
Trouble-shooting and monitoring fees ..........................
Maintenance .................................................................
$2000.00
1000.00
Total .......................................................................
12,000.00
Total .......................................................................
3,000.00
Estimate of Other Total Annual Cost
Burden: $15,000.00.
sroberts on PROD1PC70 with NOTICES
Request for Comments
Written comments and/or suggestions
from the public and affected agencies
should address one or more of the
following points: (1) Evaluate whether
the proposed collection of information
is necessary for the proper performance
of the function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
VerDate Aug<31>2005
23:08 Jun 22, 2007
Jkt 211001
For Further Information: To request
more information on the proposed
project or to obtain a copy of the data
collection plans and instruments,
contact: Dr. Patricia Wagner, Director of
Admissions & Registrar, Graduate
Partnerships Program, National
Institutes of Health, 2 Center Drive,
Building 2 / Room 2E12, Bethesda,
Maryland 20892–0234, or call 301–594–
9603 or E-mail your request, including
your address to: wagnerpa@od.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: June 18, 2007.
Michael M. Gottesman,
Deputy Director for Intramural Research,
National Institutes of Health.
[FR Doc. E7–12175 Filed 6–22–07; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
E:\FR\FM\25JNN1.SGM
25JNN1
34694
Federal Register / Vol. 72, No. 121 / Monday, June 25, 2007 / Notices
sroberts on PROD1PC70 with NOTICES
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Zscan4: A Gene Critical for Early
Embryonic Development
Description of Technology: Activation
of transcription from the embryonic
genome, known as zygotic genome
activation (ZGA), marks the key switch
from maternal to embryonic control of
development and establishes gene
expression patterns required for
continued development of the embryo.
Genes expressed during ZGA may be
important for assisted reproductive
technologies, and in stem cell research
and development.
The inventors have identified Zscan4,
a gene expressed solely in late 2-cell
stage embryos and in embryonic stem
cells. Inhibition of Zscan4 expression
using siRNA techniques delays
progression from the 2-cell stage to the
4-cell stage, and produces blastocysts
that fail to implant in the mouse
embryo. Thus, Zscan4 plays an essential
role in early embryonic development,
with potential applications for the
development of stem cell therapeutics.
The invention discloses methods of
promoting blastocyst outgrowth of
embryonic stem cells. Also disclosed are
Zscan4 expression vectors and methods
of identifying a subpopulation of stem
cells expressing Zscan4.
Applications: Development of stem
cell therapeutics; Assisted reproduction
technologies and studies of early
embryonic development.
Market: State and federal funding for
stem cell research is predicted to reach
$10 billion by 2018.
Development Status: Early stage.
Inventors: Minoru S. Ko et al. (NIA).
Publications: Geppino Falco et al.
Zscan4: A novel gene expressed
exclusively in late 2-cell embryos and
embryonic stem cells. Dev Biol., in
press.
Patent Status: U.S. Provisional
Application No. 60/920,215 filed 26 Mar
2007 (HHS Reference No. E–088–2007/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Tara L. Kirby,
Ph.D.; 301/435–4426;
tarak@mail.nih.gov.
Retrovirus Packaging Cell Lines Based
on Gibbon Ape Leukemia Virus
Description of Technology: Gene
therapy and gene transfer have recently
VerDate Aug<31>2005
23:08 Jun 22, 2007
Jkt 211001
been recognized as effective therapeutic
tools to combat diseases. Accordingly,
market demands for vectors and carriers
to facilitate such interventions have
surged in recent years. Retroviral
vectors provide an efficient and safe
means of gene transfer to eukaryotic
cells. The present invention relates to
genetic engineering involving retrovirus
packaging cells that produce retroviral
vectors. Specifically, the invention
involves the expression plasmids
encoding the envelope glycoproteins of
a family of primate type C retrovirus,
namely, the Gibbon Ape leukemia virus
(GALV). Recombinant vectors derived
from murine leukemia virus (MLV) have
been widely used to introduce genes in
human gene therapy clinical trials. A
key determinant for their use in clinical
gene therapy is the availability of
packaging cell lines capable of
producing large amounts of virus with
identical titers. The present invention
describes the packaging cell lines that
produce MLV-based gene transfer
vectors with the envelope from gibbon
ape leukemia virus. Retroviral vectors
produced are of high titer and have an
expanded host range providing a means
for gene transfer to a wide range of
animal species. The gene transfer
vectors produced are non-infectious and
there was no evidence of production of
helper virus, making these vectors safe.
These cell lines are critical for
producing large amounts of
standardized vector necessary for
efficient in vivo and ex vivo gene
transfer. Therefore, this invention has a
significant commercial application as a
tool in the development of diagnostic
and therapeutic interventions related to
gene transfer and gene therapy.
Inventors: Maribeth V. Eiden (NIMH)
et al.
Patent Status: U.S. Patent No.
5,470,726 issued 28 Nov 1995 (HHS
Reference No. E–201–1991/0–US–02).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Tara L. Kirby,
Ph.D.; 301/435–4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Mental Health,
Laboratory of Cellular and Molecular
Regulation, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the Gibbon Ape
leukemia virus (GALV) packaging cell
line. Please contact Suzanne Winfield at
winfiels@mail.nih.gov for more
information.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Dated: June 14, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–12174 Filed 6–22–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center on Minority Health and
Health Disparities; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center
on Minority Health and Health
Disparities Special Emphasis Panel;
NCMHD Conference Grant Application.
Date: July 19, 2007.
Time: 8 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Two Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Robert Nettey, MD,
Scientific Review Administrator,
National Institute on Minority Health,
and Health Disparities, 6707 Democracy
Blvd., Suite 800, Bethesda, MD 20892,
301–496–3996.
Dated: June 15, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–3080 Filed 6–22–07; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\25JNN1.SGM
25JNN1
]]>Agencies
[Federal Register Volume 72, Number 121 (Monday, June 25, 2007)]
[Notices]
[Pages 34693-34694]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12174]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the
[[Page 34694]]
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804;
telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential
Disclosure Agreement will be required to receive copies of the patent
applications.
Zscan4: A Gene Critical for Early Embryonic Development
Description of Technology: Activation of transcription from the
embryonic genome, known as zygotic genome activation (ZGA), marks the
key switch from maternal to embryonic control of development and
establishes gene expression patterns required for continued development
of the embryo. Genes expressed during ZGA may be important for assisted
reproductive technologies, and in stem cell research and development.
The inventors have identified Zscan4, a gene expressed solely in
late 2-cell stage embryos and in embryonic stem cells. Inhibition of
Zscan4 expression using siRNA techniques delays progression from the 2-
cell stage to the 4-cell stage, and produces blastocysts that fail to
implant in the mouse embryo. Thus, Zscan4 plays an essential role in
early embryonic development, with potential applications for the
development of stem cell therapeutics. The invention discloses methods
of promoting blastocyst outgrowth of embryonic stem cells. Also
disclosed are Zscan4 expression vectors and methods of identifying a
subpopulation of stem cells expressing Zscan4.
Applications: Development of stem cell therapeutics; Assisted
reproduction technologies and studies of early embryonic development.
Market: State and federal funding for stem cell research is
predicted to reach $10 billion by 2018.
Development Status: Early stage.
Inventors: Minoru S. Ko et al. (NIA).
Publications: Geppino Falco et al. Zscan4: A novel gene expressed
exclusively in late 2-cell embryos and embryonic stem cells. Dev Biol.,
in press.
Patent Status: U.S. Provisional Application No. 60/920,215 filed 26
Mar 2007 (HHS Reference No. E-088-2007/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Tara L. Kirby, Ph.D.; 301/435-4426;
tarak@mail.nih.gov.
Retrovirus Packaging Cell Lines Based on Gibbon Ape Leukemia Virus
Description of Technology: Gene therapy and gene transfer have
recently been recognized as effective therapeutic tools to combat
diseases. Accordingly, market demands for vectors and carriers to
facilitate such interventions have surged in recent years. Retroviral
vectors provide an efficient and safe means of gene transfer to
eukaryotic cells. The present invention relates to genetic engineering
involving retrovirus packaging cells that produce retroviral vectors.
Specifically, the invention involves the expression plasmids encoding
the envelope glycoproteins of a family of primate type C retrovirus,
namely, the Gibbon Ape leukemia virus (GALV). Recombinant vectors
derived from murine leukemia virus (MLV) have been widely used to
introduce genes in human gene therapy clinical trials. A key
determinant for their use in clinical gene therapy is the availability
of packaging cell lines capable of producing large amounts of virus
with identical titers. The present invention describes the packaging
cell lines that produce MLV-based gene transfer vectors with the
envelope from gibbon ape leukemia virus. Retroviral vectors produced
are of high titer and have an expanded host range providing a means for
gene transfer to a wide range of animal species. The gene transfer
vectors produced are non-infectious and there was no evidence of
production of helper virus, making these vectors safe. These cell lines
are critical for producing large amounts of standardized vector
necessary for efficient in vivo and ex vivo gene transfer. Therefore,
this invention has a significant commercial application as a tool in
the development of diagnostic and therapeutic interventions related to
gene transfer and gene therapy.
Inventors: Maribeth V. Eiden (NIMH) et al.
Patent Status: U.S. Patent No. 5,470,726 issued 28 Nov 1995 (HHS
Reference No. E-201-1991/0-US-02).
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: Tara L. Kirby, Ph.D.; 301/435-4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Mental Health, Laboratory of Cellular and Molecular Regulation, is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
the Gibbon Ape leukemia virus (GALV) packaging cell line. Please
contact Suzanne Winfield at winfiels@mail.nih.gov for more information.
Dated: June 14, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-12174 Filed 6-22-07; 8:45 am]
BILLING CODE 4140-01-P
